Key Takeaways
- Volume-led growth, capacity near ceiling: Revenue rose 61% YoY on a 12% MCC volume increase and new API/O&M contributions, while MCC utilization hit ~95%, making the imminent capacity expansion critical.
- Expansion capex is the margin story: ROCE declined as capital work-in-progress swelled for the Dahej CCS plant and MCC debottlenecking; management expects asset turnover to exceed 3x and EBITDA margins to move “much ahead” of 20% as these assets come online.
- Pulp costs are climbing, not falling: Contrary to competitor commentary, management sees pulp prices “shooting northwards” and is deliberately building working capital to stock up, a near-term margin watchpoint.
- API and CCS are the next legs: The Trimax API acquisition is consolidated, and the CCS facility at Dahej awaits a mid-February environmental clearance to begin capex deployment; both carry margin profiles management says will lift the blended EBITDA above 20%.
- What to watch next quarter: Whether the Dahej environmental clearance arrives by mid-February, the ramp of expanded MCC capacity from end-February, and the trajectory of pulp costs against the stocking strategy.
Capacity Expansion & Capex Cycle
- MCC expansion imminent: Capacity is rising from ~14,000 to over 21,000 metric tons per annum, with commissioning trials underway and material trials to commence; sales from the expanded capacity are expected from end-February.
- Q4 ramp revised down: Management had earlier guided 25% utilization of the new capacity in the first quarter post-expansion, but now expects only 10% in Q4, with 25% to follow subsequently.
- Dahej CCS facility gated by clearance: Environmental clearance was expected by December but is delayed; management expects file clearance by mid-February, and only then can capex deployment begin, likely by March.
- Sigachi Arabia JV on a three-year horizon: A manufacturing facility in Riyadh is planned within three years, initially serving local and GCC markets, adding a geographic growth vector beyond the domestic expansion.
- Capex outlay: INR100 crores planned for FY24 and another INR100 crores for FY25, funding both the MCC and CCS build-outs.
- ROCE pressure is transitional: The declining ROCE trend is attributed to ongoing expansion and increased capital work-in-progress; management expects the asset turnover ratio to recover to more than 3x as new capacities become operational.
Margin Outlook & Input Costs
- MCC realization flat, volume did the work: Realization held at ~INR208 per kg YoY, so the revenue jump came entirely from quantity improvement and new segment contributions.
- Pulp prices moving against the narrative: Management contradicted a competitor’s claim of softening pulp prices, stating prices have been rising for the last couple of months and the company is increasing working capital to stock more pulp.
- CCS margins structurally higher: CCS carries better margins than existing MCC, and management expects this to lift EBITDA at the company level as the segment scales.
- API margins to inflect with regulatory approvals: Initial API margins are subdued, but management believes they will reach 20–22% once approvals from the EU region and certain Latin American countries come through; CEP has been applied and some NBISA approvals are done.
- Blended EBITDA ambition: Management expects the company as a whole to be “positive of 20% at EBITDA level” and to improve further as API contributions grow, with a two-year trajectory to move “much ahead” of the baseline 20%.
Amit Raj Sinha: “Over a two-year period, you should see us being much ahead of the basic 20% at which we have always been.”
New Business Verticals: API & CCS
- Trimax API acquisition consolidated: The 80% stake in Trimax BioSciences, an API manufacturer in Raichur, is fully consolidated for FY24; integration of systems like SOPs and HRMS is still in progress given differences in operating practices.
- API is not forward integration: Management clarified that Trimax shares the same customer profile as the excipient business, so the acquisition expands the wallet with existing pharma customers rather than moving downstream.
- CCS is a natural cross-sell: MCC binds a tablet; CCS is the disintegrant that releases the drug. Every tablet needs both, so the existing distribution network across 55–60 countries becomes a ready channel for CCS.
- CCS pricing is competition-driven: As a new entrant, Sigachi will price to win a foot in the door, using an established customer base as leverage to gain share.
- Five-year revenue mix target: Management aims for 70% or more from excipient and API, with the balance 30% from food, nutrition, and operations & management.
Amit Raj Sinha: “MCC is a binder and it binds the whole tablet together. Whereas, CCS becomes a disintegrant where it breaks up the tablet at the right point within the body to release the drug. So, every tablet which is taken in also needs to have in CCS.”
Customer & Market Strategy
- Twofold customer strategy: Increase share of wallet with existing customers, and onboard new customers as an alternate vendor before gradually building up share; lower-grade customers with poor payment terms or geopolitical risk are systematically purged over time.
- Export-domestic mix stable: Historically two-thirds export, one-third domestic, and management expects this ratio to hold with the CCS product launch.
- Market share undisclosed: Management declined to quantify market share in India or globally, calling it “a very tough call to take,” but asserted number-one status in India by installed capacity.
- O&M services a steady contributor: Partnerships with Gujarat Alkalies, ONGC, Grasim, and Lord’s Chloro Alkali generate month-on-month revenue, adding a recurring services layer to the manufacturing base.
Amit Raj Sinha: “We gradually keep purging out these set of customers and keep having better customers so that effectively over a couple of years, our customer profile only betters.”
Capital Allocation & Governance
- Promoter pledging tied to company investment: The stock split was accompanied by promoter pledging; management stated the funds raised were infused back into the company for further investment.
- Equity dilution question deflected: When asked about views on equity dilution within two to three years of IPO, management did not answer directly, stating only that focus is on growth and that all stakeholders gain from growth.
- Warrant conversion terms not agreed: On the share warrants, management said there are no agreed conversion terms; investors will infuse funds as per the company’s requirement.
- Pulp price specifics withheld: Management declined to provide indicative pulp prices, citing wide variation by mill, wood species, quality, brightness, and purity levels that make apple-to-apple comparison difficult.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| MCC expanded capacity sales | Sales from new capacity to begin | End-February 2024 |
| MCC capacity utilization ramp | 10% utilization of new capacity in Q4, then 25% subsequently | Q4 FY24, then forward |
| Dahej CCS environmental clearance | File clearance expected; capex deployment follows | Mid-February 2024 |
| FY24 capex | INR100 crores | FY24 |
| FY25 capex | INR100 crores | FY25 |
| Revenue growth | Comfortable 30% growth | FY24–25 |
| Sigachi Arabia manufacturing facility | Operational in Riyadh, serving local and GCC markets | Within three years |
| API margin target | 20–22% margins post regulatory approvals | Upon EU and Latin America approvals |
| Blended EBITDA trajectory | Move “much ahead” of baseline 20% | Over a two-year period |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Operating income | ₹111 cr, +61% YoY |
| EBITDA | ₹22.6 cr, +61.4% YoY; margin of 20.3% |
| Net profit | ₹16 cr, +65.3% YoY; PAT margin of 14.6% |
| 9M FY24 operating revenue | ₹295 cr, +28.4% YoY |
| 9M FY24 EBITDA | ₹60.3 cr, +29.7% YoY; margin of 20.45% |
| 9M FY24 net profit | ₹42 cr, PAT margin of 14.24% |
| 9M FY24 product sales | ₹269 cr, +27% YoY from ₹212 cr |
| 9M FY24 overall revenue | ₹299 cr, +27.5% YoY from ₹235 cr |
| MCC quantity sold (9M FY24) | 11,036 metric tons, +12.04% YoY from 9,850 metric tons |
| MCC realization | ~₹208 per kg, flat YoY |
| MCC capacity utilization | ~95% |
| MCC capacity expansion | From ~14,000 MTPA to >21,000 MTPA, effective Feb 2024 |
| FY24 capex | ~₹100 cr |
| FY25 capex plan | ~₹100 cr |
| Capital work in progress (9M FY24) | ₹79.13 cr, up from ₹35 cr in FY23 |
| O&M segment revenue (9M FY24) | ₹25.96 cr, expected ~₹35 cr for full FY24 |
| FY25 revenue growth guidance | ~30%, comfortable target per management |
| Asset turnover ratio target | >3x, up from current ~2–2.5x |